Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Epizyme, Inc. stock logo
EPZM
Epizyme
$1.47
$1.47
$0.41
$5.80
$247.44M-0.413.23 million shs7,960 shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$78.93
-1.3%
$84.17
$64.94
$90.04
$3.95B0.43306,647 shs359,188 shs
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
$47.99
$47.99
$19.64
$48.02
$2.27B1.051.16 million shs30,200 shs
Synthorx, Inc. stock logo
THOR
Synthorx
$67.99
$67.99
$11.05
$71.90
$2.20BN/A474,507 shsN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$76.01
$75.83
$23.77
$82.20
$3.81B-0.181.14 million shs4,322 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00%0.00%0.00%0.00%0.00%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.00%-1.26%-6.02%-1.76%+17.07%
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Synthorx, Inc. stock logo
THOR
Synthorx
0.00%0.00%0.00%0.00%0.00%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
4.1737 of 5 stars
2.34.00.03.52.81.71.9
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Synthorx, Inc. stock logo
THOR
Synthorx
N/AN/AN/AN/AN/AN/AN/AN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00
N/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.50
Moderate Buy$93.3318.25% Upside
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.00
N/AN/AN/A
Synthorx, Inc. stock logo
THOR
Synthorx
0.00
N/AN/AN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RARX, THOR, EPZM, TPTX, and PBH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Epizyme, Inc. stock logo
EPZM
Epizyme
$37.43M6.61N/AN/A($0.54) per share-2.72
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.14B3.43$5.15 per share15.34$37.04 per share2.13
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
$3M757.11N/AN/A$5.56 per share8.63
Synthorx, Inc. stock logo
THOR
Synthorx
N/AN/AN/AN/A$6.72 per shareN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$30.83M123.46N/AN/A$15.84 per share4.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Epizyme, Inc. stock logo
EPZM
Epizyme
-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$214.60M$4.2918.4016.582.4018.86%12.87%6.78%8/6/2025 (Estimated)
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
-$102.69M-$2.31N/AN/AN/AN/A-44.61%-41.60%N/A
Synthorx, Inc. stock logo
THOR
Synthorx
-$56.61M-$6.59N/AN/AN/AN/A-26.09%-24.62%N/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/A

Latest RARX, THOR, EPZM, TPTX, and PBH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q4 2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.30$1.32+$0.02$1.00$289.36 million$296.52 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
N/AN/AN/AN/AN/A
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/AN/AN/AN/AN/A
Synthorx, Inc. stock logo
THOR
Synthorx
N/AN/AN/AN/AN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Epizyme, Inc. stock logo
EPZM
Epizyme
N/A
5.35
5.19
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.55
4.20
2.82
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
0.01
14.78
14.79
Synthorx, Inc. stock logo
THOR
Synthorx
N/A
18.87
18.87
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/A
16.83
16.83

Institutional Ownership

CompanyInstitutional Ownership
Epizyme, Inc. stock logo
EPZM
Epizyme
76.45%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
99.95%
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
N/A
Synthorx, Inc. stock logo
THOR
Synthorx
66.12%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
90.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Epizyme, Inc. stock logo
EPZM
Epizyme
250168.33 million128.97 millionOptionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
54049.42 million48.72 millionOptionable
Ra Pharmaceuticals Inc stock logo
RARX
Ra Pharmaceuticals
7247.33 millionN/AOptionable
Synthorx, Inc. stock logo
THOR
Synthorx
4832.34 millionN/ANot Optionable
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
25050.07 million45.77 millionNot Optionable

Recent News About These Companies

Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance
Glass System in Turning Point Residence
Turning Point Brands Inc.
Alzheimer’s: A Turning Point?
Turning Point Brands Inc (TPB)
Cormorant Asset Management, LP's Net Worth
Solving quadratic equations - Edexcel
BMS bet looking good as Augtyro approved in ROS1-positive NSCLC
A Turning Point for Japan-US Climate Cooperation?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Epizyme stock logo

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Prestige Consumer Healthcare stock logo

Prestige Consumer Healthcare NYSE:PBH

$78.93 -1.05 (-1.31%)
Closing price 03:58 PM Eastern
Extended Trading
$78.86 -0.07 (-0.08%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Ra Pharmaceuticals stock logo

Ra Pharmaceuticals NASDAQ:RARX

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company's pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Synthorx stock logo

Synthorx NASDAQ:THOR

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.

Turning Point Therapeutics stock logo

Turning Point Therapeutics NASDAQ:TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.